BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a strong sell rating to a sell rating in a research note published on Tuesday.
Other research analysts have also issued reports about the stock. ValuEngine lowered shares of Progenics Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Wednesday, August 29th. Needham & Company LLC lifted their price objective on shares of Progenics Pharmaceuticals from $14.00 to $16.00 and gave the company a strong-buy rating in a research note on Tuesday, July 31st. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, September 25th. Finally, Jefferies Financial Group restated a buy rating and issued a $13.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Progenics Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $11.69.
NASDAQ PGNX opened at $5.30 on Tuesday. The company has a current ratio of 6.34, a quick ratio of 6.34 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $446.38 million, a price-to-earnings ratio of -5.89 and a beta of 2.81. Progenics Pharmaceuticals has a one year low of $4.68 and a one year high of $9.42.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.